Mar 27, 2026 by Bram BerkowitzDow Tumbles 800 Points and the S&P 500 Posts Its Fifth Straight Weekly Loss: What Investors Need to Know About the Worst Streak Since 2022The market struggled this week amid the ongoing war in Iran.
Mar 27, 2026 by Daniel SparksOnly a Few "Magnificent Seven" Stocks Look Like Buys Right Now. This Is One of Them.As stocks sell off, here's one of the Magnificent Seven stocks I think has fallen enough to make it a buy.
Mar 27, 2026 by Daniel SparksCrowdStrike Stock Was Absolutely Hammered This Week. Why I'm Still Not Buying.CrowdStrike's top-line growth remains impressive, but a demanding valuation leaves the stock vulnerable to emerging artificial intelligence risks.
Mar 27, 2026 by Jonathan PoncianoThis F&G Insider Spent $100,000 Buying Shares Despite a Steep Stock Plunge. Is It Time for a Turnaround?This annuities and life insurance provider saw a notable insider buy amid a year marked by sharp share price declines and sector headwinds.
Mar 27, 2026 by Catie HoganShould You Buy Lockheed Martin While It's Up 26% in 2026?If the defense budget tops $1 trillion, Lockheed stands to make a fortune.
Mar 27, 2026 by Joe TenebrusoWhy Argan Stock Ascended TodayData centers devour energy. Argan builds the power plants that feed them.
Mar 27, 2026 by Jonathan PoncianoLeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should KnowLeMaitre Vascular, a specialist in vascular medical devices, reported a notable insider sale amid strong recent share gains.
Mar 27, 2026 by Jonathan PoncianoCrinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters MoreThis biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.
Mar 27, 2026 by Keithen Drury3 No-Brainer AI Stocks to Buy Before They Soar, According to Wall StreetAnalysts think Nebius, Microsoft, and Nvidia have huge upsides.
Mar 27, 2026 by Jonathan PoncianoAlphatec CFO Sells $986K in Stock With Shares Up 9% This Past Year. Here's What Investors Should KnowThis spine-focused medtech firm, known for its surgical innovations, reported a notable insider sale amid ongoing portfolio expansion.
Mar 27, 2026 by Daniel SparksOnly a Few "Magnificent Seven" Stocks Look Like Buys Right Now. This Is One of Them.As stocks sell off, here's one of the Magnificent Seven stocks I think has fallen enough to make it a buy.
Mar 27, 2026 by Eric VolkmanWhy Corcept Therapeutics Zoomed Nearly 9% Higher This WeekIt was a historic stretch of time for the biotech.
Mar 27, 2026 by Selena MaranjianThe Market Is Down 5% in 2026. Here's the Best Dividend Stock to Buy With $10,000 Right Now.This investment offers a terrific combination of likely price appreciation along with dividend income.
Mar 27, 2026 by Jonathan PoncianoLigand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to KnowThis royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.
Mar 27, 2026 by Maurie BackmanThe 1 Retirement Budgeting Mistake Too Many People Risk MakingThis error could really trip you up.
Mar 27, 2026 by Eric VolkmanWhy Argan Stock Was a Winner This WeekThe company crushed bottom-line estimates in its final quarter of 2025.
Mar 27, 2026 by Jonathan PoncianoXenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should KnowThis clinical-stage biotech advancing neurological therapies reported a notable insider sale as it progresses its drug pipeline.
Mar 27, 2026 by Parkev Tatevosian, CFAUnfortunate News for Meta Stock InvestorsInvestors are concerned about restrictive regulations against social media companies.
Mar 27, 2026 by Motley Fool YouTubeNovo Nordisk: A Strong Contender in the Pharmaceutical ArenaCould Novo Nordisk be the hidden gem you've been searching for? Join us as we evaluate its current market position and future prospects in this insightful episode.
Mar 27, 2026 by Parkev Tatevosian, CFAAlphabet Delivers Unfortunate News for Micron Stock InvestorsThe outcome for investors could be more complex than it seems.
Mar 27, 2026 by Parkev Tatevosian, CFAIs Alphabet Stock Still a Buy?The war in Iran is driving widespread selling in the stock market.
Mar 27, 2026 by Parkev Tatevosian, CFAUp 110% in One Year, Is This Unstoppable Dividend Stock Still a Buy?The performance came from an unlikely source for this company.
Mar 27, 2026 by Parkev Tatevosian, CFAIs e.l.f. Stock a Generational Buying Opportunity?Trader barriers are increasing import prices for most businesses, including e.l.f.
